Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Odum, J.
Right arrow Articles by MacWhannell, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odum, J.
Right arrow Articles by MacWhannell, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 403-406
© 2001 European Renal Association-European Dialysis and Transplant Association


Case Reports

Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment

Jonathan Odum,1, Dominic D'Costa2, Mark Freeth3, David Taylor4, Neil Smith5 and Alan MacWhannell5

1 Departments of Renal Medicine 2 General Medicine and 3 Histopathology 4 Dermatology 5 Haematology, New Cross Hospital, Wolverhampton, UK

Keywords: cryoglobulinaemia; glomerulonephritis; immunoglobulin; vasculitis



   Introduction
 
Intravenous immunoglobulin (IVIG) is used as replacement treatment for patients with hypogammaglobulinaemic states (both primary and secondary), and due to its immunomodulatory properties is also used to treat certain autoimmune or inflammatory conditions (idiopathic thrombocytopenia purpura, Guillain–Barre syndrome, dermatomyositis, Kawasaki disease). Generally, administration of IVIG is safe, and although the incidence of reported side-effects ranges from 5–15%, these are usually mild and comprise pyrexia, headache, malaise and rash [1,2]. More rarely, serious life-threatening adverse reactions may occur including anaphylaxis (particularly in patients with IgA deficiency) [1] and acute renal failure [3]. Indeed, with respect to the latter, a recent editorial [4] has reviewed the available data regarding IVIG-associated renal impairment and has suggested that in most cases the cause is non-glomerular, but rather is secondary to proximal tubular ‘toxicity’.

In this report, we present a patient who developed cutaneous cryoglobulinaemic . . . [Full Text of this Article]



   Case
 


   Discussion
 


   Notes
 


   References
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
T. H. Brannagan III
Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies
Neurology, December 24, 2002; 59(90126): S33 - 40.
[Abstract] [Full Text]